Loading...

Fund Overview

Fund Size

Fund Size

₹321 Cr

Expense Ratio

Expense Ratio

2.37%

ISIN

ISIN

INF0QA701987

Minimum SIP

Minimum SIP

₹500

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

27 Dec 2024

About this fund

This fund has been in existence for 6 months and 4 days, having been launched on 27-Dec-24.
As of 30-Jun-25, it has a Net Asset Value (NAV) of ₹9.69, Assets Under Management (AUM) of 321.02 Crores, and an expense ratio of 2.37%.
  • Bajaj Finserv Healthcare Fund Regular Growth has given a CAGR return of -3.07% since inception.
  • The fund's asset allocation comprises around 95.48% in equities, 0.00% in debts, and 4.52% in cash & cash equivalents.
  • You can start investing in Bajaj Finserv Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

-3.07%

(Cat Avg.)

Portfolio Summaryas of 31st May 2025

Equity306.52 Cr95.48%
Others14.5 Cr4.52%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Divi's Laboratories LtdEquity27.97 Cr8.71%
Sun Pharmaceuticals Industries LtdEquity25.1 Cr7.82%
Cipla LtdEquity21.21 Cr6.61%
Apollo Hospitals Enterprise LtdEquity18.82 Cr5.86%
Net Receivables / (Payables)Cash14.5 Cr4.52%
Dr Reddy's Laboratories LtdEquity11.32 Cr3.52%
Piramal Pharma LtdEquity11.25 Cr3.50%
Biocon LtdEquity11 Cr3.43%
Emcure Pharmaceuticals LtdEquity10.91 Cr3.40%
Glenmark Pharmaceuticals LtdEquity9.03 Cr2.81%
Neuland Laboratories LtdEquity8.87 Cr2.76%
Syngene International LtdEquity8.5 Cr2.65%
GlaxoSmithKline Pharmaceuticals LtdEquity8.43 Cr2.63%
Torrent Pharmaceuticals LtdEquity7.77 Cr2.42%
Abbott India LtdEquity7.47 Cr2.33%
Pfizer LtdEquity7.21 Cr2.24%
Ipca Laboratories LtdEquity7.19 Cr2.24%
Sanofi Consumer Healthcare India LtdEquity6.67 Cr2.08%
Rainbow Childrens Medicare LtdEquity6.44 Cr2.01%
Zydus Wellness LtdEquity6.22 Cr1.94%
Dr. Lal PathLabs LtdEquity6.1 Cr1.90%
Vijaya Diagnostic Centre LtdEquity5.9 Cr1.84%
Fortis Healthcare LtdEquity5.51 Cr1.72%
Hindustan Unilever LtdEquity5.09 Cr1.58%
Shaily Engineering Plastics LtdEquity5 Cr1.56%
Alkem Laboratories LtdEquity4.87 Cr1.52%
Orchid Pharma LtdEquity4.44 Cr1.38%
Emami LtdEquity4.4 Cr1.37%
Medi Assist Healthcare Services LtdEquity4.32 Cr1.35%
Medplus Health Services LtdEquity4.29 Cr1.34%
Jubilant Pharmova LtdEquity4.11 Cr1.28%
Alembic Pharmaceuticals LtdEquity4.07 Cr1.27%
Max Healthcare Institute Ltd Ordinary SharesEquity3.94 Cr1.23%
Lupin LtdEquity3.84 Cr1.20%
Marico LtdEquity3.8 Cr1.18%
AstraZeneca Pharma India LtdEquity3.62 Cr1.13%
Mankind Pharma LtdEquity3.58 Cr1.12%
Aurobindo Pharma LtdEquity2.87 Cr0.89%
Nestle India LtdEquity2.4 Cr0.75%
Neogen Chemicals LtdEquity1.58 Cr0.49%
PB Fintech LtdEquity1.41 Cr0.44%

Allocation By Market Cap (Equity)

Large Cap Stocks

31.41%

Mid Cap Stocks

31.23%

Small Cap Stocks

32.84%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare276.63 Cr86.17%
Consumer Defensive21.9 Cr6.82%
Basic Materials6.59 Cr2.05%
Financial Services1.41 Cr0.44%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

16.03%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.98

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.79

Higher the better

Fund Managers

Nimesh Chandan

Nimesh Chandan

Since December 2024

Siddharth Chaudhary

Siddharth Chaudhary

Since December 2024

Sorbh Gupta

Sorbh Gupta

Since December 2024

Additional Scheme Detailsas of 31st May 2025

ISIN
INF0QA701987
Expense Ratio
2.37%
Exit Load
1.00%
Fund Size
₹321 Cr
Age
6 months
Lumpsum Minimum
₹500
Fund Status
Open Ended Investment Company
Benchmark
BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Bajaj Finserv Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹321.02 Cr-
Bajaj Finserv Healthcare Fund Direct Growth

Very High Risk

0.7%1.0%₹321.02 Cr-
PGIM India Healthcare Fund Direct Growth

Very High Risk

0.7%0.0%₹108.88 Cr-
PGIM India Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹108.88 Cr-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹331.66 Cr28.3%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Very High Risk

0.7%1.0%₹331.66 Cr30.5%
DSP Nifty Healthcare ETF Regular Growth

Very High Risk

0.2%-₹10.25 Cr15.5%
Kotak Healthcare Fund Direct Growth

Very High Risk

0.8%0.0%₹434.55 Cr18.2%
Kotak Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹434.55 Cr16.2%
HDFC Pharma and Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹1704.87 Cr28.3%
HDFC Pharma and Healthcare Fund Direct Growth

Very High Risk

0.8%1.0%₹1704.87 Cr29.9%
Nippon India Pharma Fund Direct Growth

Very High Risk

0.9%1.0%₹8352.16 Cr17.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth

Very High Risk

1.9%1.0%₹5507.52 Cr22.3%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Very High Risk

1.1%1.0%₹5507.52 Cr23.3%
DSP Healthcare Fund Direct Growth

Very High Risk

0.6%0.0%₹2961.36 Cr17.5%
DSP Healthcare Fund Regular Growth

Very High Risk

1.9%0.0%₹2961.36 Cr15.9%
LIC MF Healthcare Fund Direct Growth

Very High Risk

1.2%1.0%₹84.19 Cr19.0%
LIC MF Healthcare Fund Regular Growth

Very High Risk

2.5%1.0%₹84.19 Cr17.5%
quant Healthcare Fund Direct Growth

Very High Risk

0.8%1.0%₹417.03 Cr9.3%
quant Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹417.03 Cr7.5%
UTI Healthcare Fund Direct Growth

Very High Risk

1.3%1.0%₹1062.19 Cr22.8%
SBI Healthcare Opportunities Fund Direct Growth

Very High Risk

0.9%0.0%₹3689.28 Cr21.9%
Tata India Pharma & Healthcare Fund Regular Growth

Very High Risk

2.1%0.0%₹1231.67 Cr15.2%
Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk

0.6%0.0%₹1231.67 Cr16.9%
ICICI Prudential Nifty Healthcare ETF

Very High Risk

0.1%-₹144.00 Cr15.6%
SBI Healthcare Opportunities Fund Regular Growth

Very High Risk

1.9%0.0%₹3689.28 Cr20.6%
Nippon India Pharma Fund Regular Growth

Very High Risk

1.8%1.0%₹8352.16 Cr16.3%
UTI Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹1062.19 Cr21.5%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹19.07 Cr15.4%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹967.80 Cr12.2%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

1.9%1.0%₹2690.55 Cr17.2%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2690.55 Cr18.9%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹220.85 Cr16.2%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%0.0%₹220.85 Cr18.4%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹37.00 Cr15.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹814.18 Cr13.7%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.1%1.0%₹814.18 Cr15.3%
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹30.06 Cr19.6%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

qr

Rated ★ 4.3+ on

playstoreappstore

Still got questions?
We're here to help.

The NAV of Bajaj Finserv Healthcare Fund Regular Growth, as of 30-Jun-2025, is ₹9.69.
The fund's allocation of assets is distributed as 95.48% in equities, 0.00% in bonds, and 4.52% in cash and cash equivalents.
The fund managers responsible for Bajaj Finserv Healthcare Fund Regular Growth are:-
  1. Nimesh Chandan
  2. Siddharth Chaudhary
  3. Sorbh Gupta

Fund Overview

Fund Size

Fund Size

₹321 Cr

Expense Ratio

Expense Ratio

2.37%

ISIN

ISIN

INF0QA701987

Minimum SIP

Minimum SIP

₹500

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

27 Dec 2024

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

About this fund

This fund has been in existence for 6 months and 4 days, having been launched on 27-Dec-24.
As of 30-Jun-25, it has a Net Asset Value (NAV) of ₹9.69, Assets Under Management (AUM) of 321.02 Crores, and an expense ratio of 2.37%.
  • Bajaj Finserv Healthcare Fund Regular Growth has given a CAGR return of -3.07% since inception.
  • The fund's asset allocation comprises around 95.48% in equities, 0.00% in debts, and 4.52% in cash & cash equivalents.
  • You can start investing in Bajaj Finserv Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

-3.07%

(Cat Avg.)

Portfolio Summaryas of 31st May 2025

Equity306.52 Cr95.48%
Others14.5 Cr4.52%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Divi's Laboratories LtdEquity27.97 Cr8.71%
Sun Pharmaceuticals Industries LtdEquity25.1 Cr7.82%
Cipla LtdEquity21.21 Cr6.61%
Apollo Hospitals Enterprise LtdEquity18.82 Cr5.86%
Net Receivables / (Payables)Cash14.5 Cr4.52%
Dr Reddy's Laboratories LtdEquity11.32 Cr3.52%
Piramal Pharma LtdEquity11.25 Cr3.50%
Biocon LtdEquity11 Cr3.43%
Emcure Pharmaceuticals LtdEquity10.91 Cr3.40%
Glenmark Pharmaceuticals LtdEquity9.03 Cr2.81%
Neuland Laboratories LtdEquity8.87 Cr2.76%
Syngene International LtdEquity8.5 Cr2.65%
GlaxoSmithKline Pharmaceuticals LtdEquity8.43 Cr2.63%
Torrent Pharmaceuticals LtdEquity7.77 Cr2.42%
Abbott India LtdEquity7.47 Cr2.33%
Pfizer LtdEquity7.21 Cr2.24%
Ipca Laboratories LtdEquity7.19 Cr2.24%
Sanofi Consumer Healthcare India LtdEquity6.67 Cr2.08%
Rainbow Childrens Medicare LtdEquity6.44 Cr2.01%
Zydus Wellness LtdEquity6.22 Cr1.94%
Dr. Lal PathLabs LtdEquity6.1 Cr1.90%
Vijaya Diagnostic Centre LtdEquity5.9 Cr1.84%
Fortis Healthcare LtdEquity5.51 Cr1.72%
Hindustan Unilever LtdEquity5.09 Cr1.58%
Shaily Engineering Plastics LtdEquity5 Cr1.56%
Alkem Laboratories LtdEquity4.87 Cr1.52%
Orchid Pharma LtdEquity4.44 Cr1.38%
Emami LtdEquity4.4 Cr1.37%
Medi Assist Healthcare Services LtdEquity4.32 Cr1.35%
Medplus Health Services LtdEquity4.29 Cr1.34%
Jubilant Pharmova LtdEquity4.11 Cr1.28%
Alembic Pharmaceuticals LtdEquity4.07 Cr1.27%
Max Healthcare Institute Ltd Ordinary SharesEquity3.94 Cr1.23%
Lupin LtdEquity3.84 Cr1.20%
Marico LtdEquity3.8 Cr1.18%
AstraZeneca Pharma India LtdEquity3.62 Cr1.13%
Mankind Pharma LtdEquity3.58 Cr1.12%
Aurobindo Pharma LtdEquity2.87 Cr0.89%
Nestle India LtdEquity2.4 Cr0.75%
Neogen Chemicals LtdEquity1.58 Cr0.49%
PB Fintech LtdEquity1.41 Cr0.44%

Allocation By Market Cap (Equity)

Large Cap Stocks

31.41%

Mid Cap Stocks

31.23%

Small Cap Stocks

32.84%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare276.63 Cr86.17%
Consumer Defensive21.9 Cr6.82%
Basic Materials6.59 Cr2.05%
Financial Services1.41 Cr0.44%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

16.03%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.98

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.79

Higher the better

Fund Managers

Nimesh Chandan

Nimesh Chandan

Since December 2024

Siddharth Chaudhary

Siddharth Chaudhary

Since December 2024

Sorbh Gupta

Sorbh Gupta

Since December 2024

Additional Scheme Detailsas of 31st May 2025

ISIN
INF0QA701987
Expense Ratio
2.37%
Exit Load
1.00%
Fund Size
₹321 Cr
Age
6 months
Lumpsum Minimum
₹500
Fund Status
Open Ended Investment Company
Benchmark
BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Bajaj Finserv Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹321.02 Cr-
Bajaj Finserv Healthcare Fund Direct Growth

Very High Risk

0.7%1.0%₹321.02 Cr-
PGIM India Healthcare Fund Direct Growth

Very High Risk

0.7%0.0%₹108.88 Cr-
PGIM India Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹108.88 Cr-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹331.66 Cr28.3%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Very High Risk

0.7%1.0%₹331.66 Cr30.5%
DSP Nifty Healthcare ETF Regular Growth

Very High Risk

0.2%-₹10.25 Cr15.5%
Kotak Healthcare Fund Direct Growth

Very High Risk

0.8%0.0%₹434.55 Cr18.2%
Kotak Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹434.55 Cr16.2%
HDFC Pharma and Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹1704.87 Cr28.3%
HDFC Pharma and Healthcare Fund Direct Growth

Very High Risk

0.8%1.0%₹1704.87 Cr29.9%
Nippon India Pharma Fund Direct Growth

Very High Risk

0.9%1.0%₹8352.16 Cr17.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth

Very High Risk

1.9%1.0%₹5507.52 Cr22.3%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Very High Risk

1.1%1.0%₹5507.52 Cr23.3%
DSP Healthcare Fund Direct Growth

Very High Risk

0.6%0.0%₹2961.36 Cr17.5%
DSP Healthcare Fund Regular Growth

Very High Risk

1.9%0.0%₹2961.36 Cr15.9%
LIC MF Healthcare Fund Direct Growth

Very High Risk

1.2%1.0%₹84.19 Cr19.0%
LIC MF Healthcare Fund Regular Growth

Very High Risk

2.5%1.0%₹84.19 Cr17.5%
quant Healthcare Fund Direct Growth

Very High Risk

0.8%1.0%₹417.03 Cr9.3%
quant Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹417.03 Cr7.5%
UTI Healthcare Fund Direct Growth

Very High Risk

1.3%1.0%₹1062.19 Cr22.8%
SBI Healthcare Opportunities Fund Direct Growth

Very High Risk

0.9%0.0%₹3689.28 Cr21.9%
Tata India Pharma & Healthcare Fund Regular Growth

Very High Risk

2.1%0.0%₹1231.67 Cr15.2%
Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk

0.6%0.0%₹1231.67 Cr16.9%
ICICI Prudential Nifty Healthcare ETF

Very High Risk

0.1%-₹144.00 Cr15.6%
SBI Healthcare Opportunities Fund Regular Growth

Very High Risk

1.9%0.0%₹3689.28 Cr20.6%
Nippon India Pharma Fund Regular Growth

Very High Risk

1.8%1.0%₹8352.16 Cr16.3%
UTI Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹1062.19 Cr21.5%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹19.07 Cr15.4%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹967.80 Cr12.2%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

1.9%1.0%₹2690.55 Cr17.2%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2690.55 Cr18.9%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹220.85 Cr16.2%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%0.0%₹220.85 Cr18.4%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹37.00 Cr15.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹814.18 Cr13.7%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.1%1.0%₹814.18 Cr15.3%
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹30.06 Cr19.6%

Still got questions?
We're here to help.

The NAV of Bajaj Finserv Healthcare Fund Regular Growth, as of 30-Jun-2025, is ₹9.69.
The fund's allocation of assets is distributed as 95.48% in equities, 0.00% in bonds, and 4.52% in cash and cash equivalents.
The fund managers responsible for Bajaj Finserv Healthcare Fund Regular Growth are:-
  1. Nimesh Chandan
  2. Siddharth Chaudhary
  3. Sorbh Gupta
close

Get your portfolio reviewed by experts

qr

Track all your investments in one place

Download Wealth Monitor App

cross
wm logo

Track and monitor all
your investments